{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:03:43Z","timestamp":1792839823294,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2015-9189"],"award-info":[{"award-number":["2015-9189"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["HC20C0062"],"award-info":[{"award-number":["HC20C0062"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2017R1A2B4011233"],"award-info":[{"award-number":["2017R1A2B4011233"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["10079271"],"award-info":[{"award-number":["10079271"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C0790"],"award-info":[{"award-number":["HI19C0790"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cgh.2021.04.045","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T12:46:14Z","timestamp":1620132374000},"page":"427-437.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate"],"prefix":"10.1016","volume":"20","author":[{"given":"Kwan Soo","family":"Byun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonggi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Chul","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geum-Youn","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-577X","authenticated-orcid":false,"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.04.045_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","article-title":"Evolution of multi-drug resistant hepatitis B virus during sequential therapy","volume":"44","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.04.045_bib2","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.04.045_bib3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.04.045_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.29187","article-title":"Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial","volume":"66","author":"Lim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.04.045_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhep.2019.02.021","article-title":"Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs entecavir-resistant chronic hepatitis B: a 5-year clinical trial","volume":"71","author":"Lim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.04.045_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.04.045_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.04.045_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.04.045_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.04.045_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.04.045_bib11","article-title":"Tenofovir alafenamide attenuates effects of diabetes and body mass on serum alanine aminotransferase activities in patients with chronic hepatitis B","author":"Sripongpun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.04.045_bib12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2021.04.045_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cgh.2021.04.045_bib14","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521005036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521005036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:35:42Z","timestamp":1761543342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521005036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1542356521005036"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.04.045","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}